XOMA (XOMA) announced it has acquired the commercial payment and a portion of the milestone rights to IXINITY, which is marketed by Medexus Pharmaceuticals (MEDXF) for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B, from Aptevo Therapeutics (APVO). "Adding a new commercial payment stream will benefit XOMA’s shareholders as we build our base of consistent incoming cash flows to help accelerate our royalty aggregation strategy," stated Brad Sitko, Chief Investment Officer at XOMA. "IXINITY has an established niche in the Hemophilia B treatment paradigm, with near-term potential opportunities for growth, including label and geographic expansion." Under the terms of the agreement, XOMA has acquired the full commercial payment stream and a portion of Aptevo’s milestone rights related to IXINITY for $9.6 million. In the second quarter of 2023, XOMA will begin receiving a mid-single digit percentage payment stream on all IXINITY sales from January 1, 2023, into the first quarter of 2035 and also will be entitled to milestone payments.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on XOMA:
- XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio
- Xoma receives adverse decision in arbitration with licensee
- XOMA Declares Quarterly Preferred Stock Dividends
- XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy
- Xoma reports Q4 EPS (64c) vs. $1.67 last year